- The FDA has authorized the first nonprescription test to detect Covid-19, influenza, and respiratory syncytial virus (RSV).
- The test, called the Labcorp Seasonal Respiratory Virus RT-PCR DTC Test, was developed by Laboratory Corp of America Holdings LH.
- It can be sold directly to consumers online or at retail.
- A person can self-collect a nasal swab sample at home and then send that sample to Labcorp for testing.
- According to Wall Street Journal, the test kit costs $169 but comes at no upfront cost to those who meet clinical guidelines and have insurance, a Labcorp spokesperson said.
- People without insurance would have to pay upfront when ordering a kit. A federal program meant to cover Covid-19 testing and treatment for those without an insurance ended in March after officials said it ran out of funds.
- Results are delivered through an online portal, with a follow-up from a healthcare provider if the outcome is positive or invalid.
- Price Action: LH shares closed at $242.38 on Monday.
- Photo by Mufid Majnun on Unsplash
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: NewsHealth CareFDAGeneralBriefsCOVID-19 CoronavirusDiagnosticsHealth CareHealth Care Services
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in